RU2006133540A - Фуросемидные модуляторы нм74 - Google Patents
Фуросемидные модуляторы нм74 Download PDFInfo
- Publication number
- RU2006133540A RU2006133540A RU2006133540/04A RU2006133540A RU2006133540A RU 2006133540 A RU2006133540 A RU 2006133540A RU 2006133540/04 A RU2006133540/04 A RU 2006133540/04A RU 2006133540 A RU2006133540 A RU 2006133540A RU 2006133540 A RU2006133540 A RU 2006133540A
- Authority
- RU
- Russia
- Prior art keywords
- contain
- combination
- substituted
- heteroatom
- branched
- Prior art date
Links
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 title 1
- 229960003883 furosemide Drugs 0.000 title 1
- 125000005842 heteroatom Chemical group 0.000 claims abstract 69
- 101001035752 Homo sapiens Hydroxycarboxylic acid receptor 3 Proteins 0.000 claims abstract 14
- 102100039356 Hydroxycarboxylic acid receptor 3 Human genes 0.000 claims abstract 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 239000001257 hydrogen Substances 0.000 claims abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 7
- 230000007781 signaling event Effects 0.000 claims abstract 4
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 125000000304 alkynyl group Chemical group 0.000 claims 12
- 239000000556 agonist Substances 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229940125425 inverse agonist Drugs 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54601104P | 2004-02-20 | 2004-02-20 | |
| US60/546,011 | 2004-02-20 | ||
| PCT/US2005/004108 WO2005082350A1 (en) | 2004-02-20 | 2005-02-10 | Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006133540A true RU2006133540A (ru) | 2008-03-27 |
Family
ID=34910746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006133540/04A RU2006133540A (ru) | 2004-02-20 | 2005-02-10 | Фуросемидные модуляторы нм74 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7232811B2 (https=) |
| EP (1) | EP1718292A1 (https=) |
| JP (1) | JP2007523166A (https=) |
| KR (1) | KR20060127141A (https=) |
| CN (1) | CN1921845A (https=) |
| AR (1) | AR047747A1 (https=) |
| AU (1) | AU2005216879B2 (https=) |
| BR (1) | BRPI0506792A (https=) |
| CA (1) | CA2557444A1 (https=) |
| CR (1) | CR8528A (https=) |
| EC (1) | ECSP066777A (https=) |
| IL (1) | IL177086A (https=) |
| MA (1) | MA28373A1 (https=) |
| ME (1) | MEP21108A (https=) |
| MX (1) | MXPA06008612A (https=) |
| NO (1) | NO20064237L (https=) |
| NZ (1) | NZ548830A (https=) |
| RS (1) | RS20060473A (https=) |
| RU (1) | RU2006133540A (https=) |
| SG (1) | SG164305A1 (https=) |
| TN (1) | TNSN06234A1 (https=) |
| TW (1) | TW200538109A (https=) |
| WO (1) | WO2005082350A1 (https=) |
| ZA (1) | ZA200606679B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008283B2 (en) | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| WO2004083388A2 (en) | 2003-03-14 | 2004-09-30 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| CN101115726A (zh) | 2004-12-03 | 2008-01-30 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| WO2007079470A2 (en) * | 2006-01-03 | 2007-07-12 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| AR059021A1 (es) * | 2006-01-18 | 2008-03-05 | Schering Corp | Moduladores de receptores cannabinoides |
| JP2010508300A (ja) * | 2006-10-26 | 2010-03-18 | フライン、ギャリー・エー． | アクアポリン修飾因子並びに浮腫および体液平衡異常の治療のためのそれらの使用方法 |
| US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| US8623873B2 (en) * | 2007-06-28 | 2014-01-07 | Intervet Inc. | Substituted piperazines as CB1 antagonists |
| US20100286160A1 (en) * | 2007-06-28 | 2010-11-11 | Intervet Inc. | Substituted piperazines as cb1 antagonists |
| LT6401B (lt) | 2015-07-28 | 2017-06-12 | Vilniaus Universitetas | Karboanhidrazės selektyvūs inhibitoriai |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1260155A (en) * | 1969-04-29 | 1972-01-12 | Leo Pharm Prod Ltd | Sulphonamido anthranilic acid derivatives |
| US3875150A (en) | 1969-04-29 | 1975-04-01 | Leo Pharm Prod Ltd | New sulfamyl-anthranilic acids |
| DE2206424A1 (de) * | 1971-02-15 | 1972-08-24 | Dumex Ltd As | Verfahren zur Herstellung von N-substituierten Anthranilsäurederivaten |
| DE2247828A1 (de) * | 1972-09-29 | 1974-04-04 | Hoechst Ag | Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung |
| DE2406972C3 (de) * | 1974-02-14 | 1979-07-19 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren |
| DE2718871C3 (de) * | 1977-04-28 | 1980-07-17 | Hoechst Ag, 6000 Frankfurt | N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck |
| US4406896A (en) * | 1979-12-20 | 1983-09-27 | Merck & Co., Inc. | Adjuvants for rectal delivery of drug substances |
| DE3006686A1 (de) * | 1980-02-22 | 1981-08-27 | Hoechst Ag, 6000 Frankfurt | 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel |
| DE3041812A1 (de) * | 1980-11-06 | 1982-06-16 | Hoechst Ag, 6000 Frankfurt | Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel |
| DE3101960A1 (de) * | 1981-01-22 | 1982-09-02 | Hoechst Ag, 6000 Frankfurt | "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung" |
| US5256687A (en) * | 1985-09-09 | 1993-10-26 | Hoechst Aktiengesellschaft | Pharmaceutical composition for the treatment of high blood pressure |
| JPH0720862B2 (ja) * | 1989-01-27 | 1995-03-08 | ヘキスト・アクチエンゲゼルシヤフト | 吸入用喘息治療剤 |
| EP1007563A4 (en) * | 1997-06-12 | 2003-04-16 | Smithkline Beecham Corp | HM74A RECEPTOR |
| GB0021484D0 (en) * | 2000-09-01 | 2000-10-18 | Boehringer Ingelheim Pharma | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| DE10060809A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
| US20030109673A1 (en) * | 2002-10-04 | 2003-06-12 | Xiao Yonghong | Regulation of human hm74-like g protein coupled receptor |
-
2005
- 2005-02-10 BR BRPI0506792-8A patent/BRPI0506792A/pt not_active IP Right Cessation
- 2005-02-10 JP JP2006554129A patent/JP2007523166A/ja active Pending
- 2005-02-10 CA CA002557444A patent/CA2557444A1/en not_active Abandoned
- 2005-02-10 WO PCT/US2005/004108 patent/WO2005082350A1/en not_active Ceased
- 2005-02-10 MX MXPA06008612A patent/MXPA06008612A/es active IP Right Grant
- 2005-02-10 EP EP05713210A patent/EP1718292A1/en not_active Withdrawn
- 2005-02-10 SG SG200901539-7A patent/SG164305A1/en unknown
- 2005-02-10 RS RSP-2006/0473A patent/RS20060473A/sr unknown
- 2005-02-10 AU AU2005216879A patent/AU2005216879B2/en not_active Ceased
- 2005-02-10 NZ NZ548830A patent/NZ548830A/en unknown
- 2005-02-10 RU RU2006133540/04A patent/RU2006133540A/ru not_active Application Discontinuation
- 2005-02-10 ME MEP-211/08A patent/MEP21108A/xx unknown
- 2005-02-10 CN CNA2005800054570A patent/CN1921845A/zh active Pending
- 2005-02-10 KR KR1020067016657A patent/KR20060127141A/ko not_active Withdrawn
- 2005-02-14 US US11/057,587 patent/US7232811B2/en not_active Expired - Fee Related
- 2005-02-18 TW TW094104731A patent/TW200538109A/zh unknown
- 2005-02-18 AR ARP050100596A patent/AR047747A1/es not_active Application Discontinuation
-
2006
- 2006-07-24 CR CR8528A patent/CR8528A/es not_active Application Discontinuation
- 2006-07-25 IL IL177086A patent/IL177086A/en not_active IP Right Cessation
- 2006-07-28 TN TNP2006000234A patent/TNSN06234A1/en unknown
- 2006-08-11 ZA ZA200606679A patent/ZA200606679B/xx unknown
- 2006-08-18 EC EC2006006777A patent/ECSP066777A/es unknown
- 2006-08-29 MA MA29295A patent/MA28373A1/fr unknown
- 2006-09-19 NO NO20064237A patent/NO20064237L/no not_active Application Discontinuation
-
2007
- 2007-05-07 US US11/745,131 patent/US7556931B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005216879A1 (en) | 2005-09-09 |
| BRPI0506792A (pt) | 2007-05-22 |
| CR8528A (es) | 2007-06-08 |
| AR047747A1 (es) | 2006-02-15 |
| RS20060473A (sr) | 2008-08-07 |
| TW200538109A (en) | 2005-12-01 |
| US7232811B2 (en) | 2007-06-19 |
| CN1921845A (zh) | 2007-02-28 |
| WO2005082350A8 (en) | 2005-12-08 |
| TNSN06234A1 (en) | 2007-12-03 |
| NZ548830A (en) | 2010-03-26 |
| AU2005216879B2 (en) | 2009-12-10 |
| SG164305A1 (en) | 2010-09-29 |
| US20070213391A1 (en) | 2007-09-13 |
| JP2007523166A (ja) | 2007-08-16 |
| IL177086A (en) | 2010-06-16 |
| KR20060127141A (ko) | 2006-12-11 |
| US20050187280A1 (en) | 2005-08-25 |
| WO2005082350A1 (en) | 2005-09-09 |
| MEP21108A (en) | 2010-06-10 |
| EP1718292A1 (en) | 2006-11-08 |
| MA28373A1 (fr) | 2006-12-01 |
| IL177086A0 (en) | 2006-12-10 |
| NO20064237L (no) | 2006-09-19 |
| US7556931B2 (en) | 2009-07-07 |
| ZA200606679B (en) | 2008-01-30 |
| ECSP066777A (es) | 2006-11-16 |
| CA2557444A1 (en) | 2005-09-09 |
| MXPA06008612A (es) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006133540A (ru) | Фуросемидные модуляторы нм74 | |
| AR038863A1 (es) | Uso de un inhibidor de garft y/o de aicarft y de un agente antitoxico para preparar un medicamento para destruir selectivamente celulas mtap-deficientes de un mamifero | |
| PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CL2009000323A1 (es) | Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c. | |
| RU2010101416A (ru) | Профилактическое/лекарственное средство от рака | |
| PE20060693A1 (es) | Nuevos derivados de trifluorometansulfonanilida oxamida eter | |
| CL2009000324A1 (es) | Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c. | |
| PE20110102A1 (es) | Derivados de n-(2-oxo-2-pirrolidinil-1-il)etil-2-amino-acetamida como inhibidores de proteinas de apoptosis (iap) | |
| EA200401019A1 (ru) | Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества | |
| ECSP078003A (es) | Inhibidores de aspartil proteasas | |
| EA200700185A1 (ru) | Производные хиназолиндиона в качестве ингибиторов parp | |
| EA200401613A1 (ru) | Лекарственное средство для лечения рака | |
| SV2002000245A (es) | Oxazolidinonas substituidas y su uso ref. lea 34122-sv | |
| EA200700189A1 (ru) | Производные хиназолина в качестве ингибиторов parp | |
| PE20080706A1 (es) | Arilmidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
| EA200301215A1 (ru) | Лиганды рецепторов 5-ht и их применение | |
| CY1112751T1 (el) | Μεθοδος διαμορφωσης του συζευγμενου με πρωτεϊνη g υποδοχεα gpr119 και επιλεγμενες ενωσεις | |
| EA200300919A1 (ru) | N-замещенные неарильные гетероциклические антагонисты nmda/nr2b | |
| RU2003125270A (ru) | Ингибиторы крузипаина и других цистеинпротеаз | |
| BRPI0508464B8 (pt) | sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| ES2528363T3 (es) | Tratamiento para el cáncer | |
| RU2012114718A (ru) | Пиридиновые соединения конденсированного кольца как подтип-селективные модуляторы рецепторов сфингозин-1-фосфата-2 (s1p2) | |
| PE20040929A1 (es) | Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20091001 |